Andrew E Baum

Learn More
In a preliminary study to determine the safety and minimal effective dose in patients with impaired hepatic function, the cholecystographic agent iopronic acid (Oravue, research contrast material from Squibb) was well tolerated in single oral doses of 1.5, 3.0, 4.5, or 6.0 g. None of the patients experienced clinical adverse reactions. The radiologic(More)
  • 1